Global Asthma & COPD Therapeutics Market (By Type - Anti-inflammatory drugs (Inhaled Corticosteroids (ICS), Bronchodilator Monotherapy (Short-acting beta2-agonist (SABAs), Long-acting beta2-agonist (LABAs)), Others; By Nation – The US, Germany, France, Japan & China)) Market Outlook 2025

May 2019 | 85 pages | ID: G4EDB042DD5EN
Rockville Research

Abstracts

Demand for combination therapies for treatment of respiratory diseases has been on increasing spree. COPD medications such as long-acting beta-2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) combination in inhaler is one of the latest therapeutics being used for treatment of Asthma and COPD.

The report “Global Asthma & COPD Therapeutics Market (By Type - Anti-inflammatory drugs (Inhaled Corticosteroids (ICS), Bronchodilator Monotherapy (Short-acting beta2-agonist (SABAs), Long-acting beta2-agonist (LABAs)), Others; By Nation – The US, Germany, France, Japan & China)) Market Outlook 2025” provides in-depth analysis of the current scenario, detailed market outlook of the global Asthma & COPD therapeutics market overall as well as across various geographies. Geographical analysis is done across major markets such as the US, Japan, China, Germany & France.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global Asthma & COPD therapeutics market. The report has been segmented as following:-

Geographical Coverage

• North America – The US
• Europe – Germany & France
• Asia Pacific – Japan & China

Market Segmentation

• Anti-inflammatory drugs - Inhaled Corticosteroids (ICS)
• Bronchodilator Monotherapy - Short-acting beta2-agonist (SABAs), Long-acting beta2-agonist (LABAs)
• Others

Key Vendors

• AstraZeneca plc
• GlaxoSmithKline plc
• F. Hoffmann-La Roche AG
• Novartis AG
• Merck & Co., Inc.

Contents

1. EXECUTIVE SUMMARY

2. RESEARCH METHODOLOGY

3. RESPIRATORY DISEASES

3.1 Background
3.2 Types
3.3 Asthma
  3.3.1 Overview
  3.3.2 Treatment
COPD
  3.4.1 Overview
  3.4.2 Treatment

4. MARKET ANALYSIS

4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
  4.2.1 Market Share by Disease
  4.2.2 Market Share by Segments
  4.2.3 Market Share by Therapeutic Classes
Figure: Global Asthma & COPD Market Share by Therapeutic Classes (2018)
  4.2.4 Market Share by Nations

5. TREATMENT

5.1 Anti-inflammatory drugs
  5.1.1 Inhaled Corticosteroids (ICS)
    5.1.1.1 Overview
    5.1.1.2 Market Sizing (Actual & Forecasted)
5.2 Bronchodilator Monotherapy
  5.2.1 Long Acting Beta Agonists (LABA)
    5.2.1.1 Overview
    5.2.1.1 Market Sizing (Actual & Forecasted)
  5.2.2 Short Acting Beta Agonists (SABA)
    5.2.2.1 Overview
    5.2.2.2 Market Sizing (Actual & Forecasted)
5.3 Others
  5.3.1 Overview
  5.3.2 Market Sizing (Actual & Forecasted)

6. COUNTRY ANALYSIS

6.1 The US
  6.1.1 Market Sizing (Actual & Forecasted)
6.2 Germany
  6.2.1 Market Sizing (Actual & Forecasted)
6.3 France
  6.3.1 Market Sizing (Actual & Forecasted)
6.4 Japan
  6.4.1 Market Sizing (Actual & Forecasted)
6.5 China
  6.5.1 Market Sizing (Actual & Forecasted)

7. MARKET DYNAMICS

7.1 Industry Trends & Development
  7.1.1 Connected Health Solutions
  7.1.2 Higher Demand for Combination Therapies
  7.1.3 Advent of Stem Cell Therapy
7.2 Growth Drivers
  7.2.1 Prevalence of Respiratory Diseases
  7.2.2 Environmental Pollution
  7.2.3 Government Impetus
  7.2.4 Rise in Number of Smokers
  7.2.5 Growing Geriatric Population
7.3 Challenges
  7.3.1 Stringent Regulatory Compliance
  7.3.2 Patent Expiration of Drugs
  7.3.3 Side-Effects of Drugs

8. COMPETITIVE LANDSCAPE

8.1 Drugs Clinical Pipeline
8.2 Financial Analysis
8.3 Market Share Analysis

9. COMPANY PROFILES

9.1 AstraZeneca plc
9.2 GlaxoSmithKline plc
9.3 F. Hoffmann-La Roche AG
9.4 Novartis AG
9.5 Merck & Co., Inc.